# US 2001/0025031 A1 · HFGAN72 receptor genomic DNA, variants thereof, and methods of use thereof in diagnostic applications

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0025031 A1
- Document ID: US20010025031A1
- Status: Published application
- Kind: A1
- Application number: 09/828,538
- Filed: 2001-04-06
- Published: 2001-09-27
- Earliest claimed: 1998-06-08
- Inventors: Catherine E. Ellis; Cheni Kwok; Nicola J. Bodsworth; Wendy Halsey; Stephanie Van Horn
- Web page: https://patentgrep.com/patent/US20010025031A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12Q 1/6883: for diseases caused by alterations of genetic material
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to HFGAN72 receptor polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides and polypeptides, as well as variants thereof, for applications, which relate, in part, to research, diagnostic and clinical arts.

## Claims

### Claim 1

An isolated polynucleotide comprising a region selected from the group consisting of:
a sequence having at least a 95% identity to sequence selected from the group consisting of: SEQ ID NOs:1-18.

### Claim 2 (depends on 1)

An isolated polynucleotide according to claim 1, wherein said region is a genomic DNA.

### Claim 3

An isolated polynucleotide comprising a sequence selected from the group consisting of:
intron 1, 2, 3, 4, 5, 6 and 7.

### Claim 4

An isolated polypeptide encoded by a polynucleotide comprising a sequence selected from the group consisting of:
intron 1, 2, 3, 4, 5, 6 and 7.

### Claim 5

An isolated polynucleotide comprising a HFGAN72 receptor exon.

### Claim 6 (depends on 5)

The isolated polynucleotide of claim 5 having the sequence in SEQ ID NOs:2, 4, 5, 8, 10, 12, 14, and 17.

### Claim 7

An isolated polynucleotide consisting of a sequence selected from the group consisting of:
exon 1, 2, 3, 4, 5, 6, 7 and 8.

### Claim 8

An isolated polypeptide encoded by a polynucleotide consisting of a sequence selected from the group consisting of:
exon 1, 2, 3, 4, 5, 6, 7, and 8.

### Claim 9 (depends on 1)

An expression vector comprising cis-acting control elements effective for expression in a host cell of an operatively linked polynucleotide according to claim 1.

### Claim 10 (depends on 9)

An expression vector according to claim 9, wherein said control elements are effective for inducible expression of said polynucleotide in said host cell.

### Claim 11 (depends on 1)

A process for making a polypeptide, comprising the step of expressing in a host cell a polynucleotide according to claim 1.

### Claim 12 (depends on 9)

A host cell genetically engineered with the vector of claim 9.

### Claim 13 (depends on 12)

A process for producing a polypeptide comprising the step of: expressing from the host cell of claim 12 the polypeptide encoded by said DNA.

### Claim 14

A method for determining a HFGAN72 receptor-encoding polynucleotide in a sample, comprising the steps of:
(a) hybridizing to a sample a probe specific for said polynucleotide under conditions effective for said probe to hybridize specifically to said polynucleotide; and
(b) determining the hybridization of said probe to polynucleotides in said sample, wherein said probe comprises its sequence a region of 20 or more base pairs at least 95% identical to the polynucleotide sequence of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, and 17.

### Claim 15

A method for determining a HFGAN72 receptor-encoding polynucleotide in a sample, comprising the steps of:
(a) hybridizing to a sample a probe specific for said polynucleotide under conditions effective for said probe to hybridize specifically to said polynucleotide; and
(b) determining the hybridization of said probe to polynucleotides in said sample, wherein said probe comprises its sequence a region of 20 or more base pairs at least 95% identical to the polynucleotide sequence of SEQ ID NOs:2, 4, 6, 8, 10, 12, and 17.

### Claim 16 (depends on 8)

A method for the treatment of a patient having need of HFGAN72 receptor comprising the step of: administering to the patient a therapeutically effective amount of the polypeptide of claim 8.

### Claim 17 (depends on 16)

The method of claim 16 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide in vivo.

### Claim 18 (depends on 8)

A process for diagnosing a disease or a susceptibility to a disease related to an under-expression of the polypeptide of claim 8 comprising the step of:
determining a mutation in a nucleic acid sequence encoding said polypeptide.

### Claim 19 (depends on 8)

A diagnostic process comprising:
analyzing for the presence of the polypeptide of claim 8 in a sample derived from a host.

### Claim 20

A method of detecting presence of or absence of variations in HFGAN72 receptor polynucleotides in an individual from that of a polynucleotide sequence selected from the group consisting of: SEQ ID NOs:1-18, comprising the step of:
comparing the HFGAN72 receptor polynucleotide sequences of the individual with a polynucleotide sequence selected from the group consisting of: SEQ ID NOs:1 - 18.

### Claim 21

An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
(a) a polynucleotide sequence having at least a 95% identity to a nucleotide sequence encoding the polypeptide expressible from the cDNA insert deposited at the ATCC with Deposit Number 98806; and
(b) a nucleotide sequence complementary to the nucleotide sequence of (a).

### Claim 22

An isolated polynucleotide sequence comprising the variant HFGAN72 receptor genomic polynucleotide sequence set forth in SEQ ID NOs:21 and 22.

### Claim 23

An isolated polypeptide sequence comprising the variant HFGAN72 amino acid sequence set forth in SEQ ID NO:24.
